Purpose/objectivesHemangiopericytomas are rare central nervous system (CNS) tumors. We sought to investigate existing clinical management strategies and overall survival (OS) among patients with hemangiopericytomas of the CNS. Methods/materialsAll patients diagnosed with CNS hemangiopericytoma from 2004 to 2014 in the National Cancer Database were included. Clinical and treatment-related characteristics were analyzed for an association with OS following diagnosis using univariable and multivariable analyses. ResultsNine-hundred and eighty-one patients were included (0.22% of all CNS tumors). At diagnosis, 22 patients had spinal tumors (2%), 21 patients had multifocal tumors (2%) 28 had disseminated disease (3%), and the remainder were unifocal intracranial tumors. Patients either underwent surgical resection and radiation (48%), surgery alone (37%), radiation alone (6%), or biopsy alone (9%). Of patients with known extent of resection, 53% underwent gross total resection, and, of patients with known radiation modality, 15% received stereotactic radiosurgery. Among the total cohort, 3 and 10year OS was 87% and 59%, respectively. On multivariable analysis, factors associated with inferior OS included age (HR=1.05, p<0.001), WHO grade (p<0.001), multifocal disease (HR=2.59, p=0.04), disseminated disease (HR=2.67, p=0.01), and chemotherapy (HR=2.66, p=0.01). Patients receiving surgery alone or surgery and radiation demonstrated improved OS compared to biopsy alone (HR=0.45, p=0.01 and HR=0.47, p=0.02, respectively). However radiation utilization did not impact OS (p=0.691). ConclusionsThe present data provide large-scale prognostic information from a contemporary cohort of patients with hemangiopericytoma and support an initial attempt at surgical extirpation. The benefits of ionizing radiation are likely limited to improved local control and neurologic function.